1 arrested, 1 at large after Altoona traffic stop leads to drugs
ALTOONA, Pa. (WTAJ) — A traffic stop in Altoona led to a drug bust and two men being charged; however, one of them is still at large.
Altoona police announced the arrest of Rafiq Dandridge, 30, and issued an arrest warrant for Terrance Mitchell, 34, both of Philadelphia, after a traffic stop on the 100 block of 6th Avenue at around 1:20 p.m. Saturday, May 31.
According to police, the traffic stop was initiated after spotting a vehicle from Philadelphia with an expired registration. The driver, Mitchell, was found to be on parole for various drug violations. Dandridge, the passenger, had a warrant for his arrest out of Montgomery County.
While speaking with the duo, police alleged they had conflicting stories as to why they were in Altoona. This prompted 9 Pongo to join and perform a vehicle sniff for the presence of drugs — which Pongo allegedly gave a positive alert.
Philadelphia native found with $23K worth of drugs in Altoona bust
Police arrested Dandridge on his active warrant and released Mitchell. The vehicle was impounded to obtain a search warrant. Police said the following was found once the warrant was approved:
37 glassine packets stamped 'Oreo' and 'Dennis Rodman' containing suspected methamphetamine
Four baggies with suspected fentanyl
Four baggies containing suspected crack, 14 grams
One baggie of suspected psilocybin mushrooms, 4 grams
Both men were charged with possession with intent to distribute.
Dandridge was placed in Blair County Prison in lieu of $100,000 cash bail.Mitchell remains at large with an active arrest warrant through the Altoona Police Department.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
Simulations Plus Releases ADMET Predictor® 13
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus®—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams. 'ADMET Predictor has long been the standard for discovery modeling platforms in the pharmaceutical space,' said David Miller, Vice President of Cheminformatics of Simulations Plus. 'Before artificial intelligence and machine learning became industry buzzwords, ADMET Predictor was already leveraging these technologies to help our clients design and optimize new compounds. By tightly integrating mechanistic simulation with AI/ML and wrapping it in a powerful, customizable software platform that can be seamlessly deployed into existing workflows, we are now making predictions more accurate and easier to access for our clients around the world.' Learn more about ADMET Predictor 13 or request a demo. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
Business Wire
an hour ago
- Business Wire
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom from June 13–16, 2025. Details are as follows: Potential for Sebetralstat to Address Pseudo-allergic Reaction Burden Secondary to Icatibant in HAE (D1.324): Sally L. Hampton, Paul K. Audhya, Michael D. Smith, Christopher M. Yea. Results will be shared as a poster presentation from 12:00–1:00 pm BST in the Poster Zone. Saturday, June 14 Psychological Burden Associated with Injectable HAE On-Demand Treatments: A Patient and Caregiver Interview Study (D2.324): Sorena Kiani-Alikhan, Aleena Banerji, Paula Busse, Timothy Craig, Patrick Yong, Rebekah Hall, Siu Hing Lo, Caleb Dixon, Paul Audhya, Alice Wang, Tomaz Garcez. Results will be shared as a late poster presentation from 12:00–1:00 pm BST in the Poster Zone. Sebetralstat for Treatment of HAE Attacks in Patients Receiving Berotralstat, Lanadelumab, or C1 Inhibitor for Long-term Prophylaxis: Interim Analysis from KONFIDENT-S (001408): Marc A. Riedl, Emel Aygören-Pürsün, Jonathan A. Bernstein, Paula J. Busse, Mauro Cancian, Danny M. Cohn, Timothy Craig, Henriette Farkas, Sorena Kiani-Alikhan, Tamar Kinaciyan, H. Henry Li, William R. Lumry, Michael E. Manning, Jason Raasch, Daniel F. Soteres, Raffi Tachdjian, H. James Wedner, James Hao, Michael D. Smith, Paul K. Audhya, Andrea Zanichelli. Results will be shared as an oral presentation from 3:36–3:48 pm BST in the Innovation Hub. Sunday, June 15 Adherence to Long-Term Prophylaxis for Hereditary Angioedema and the Impact on On-demand Treatment Claims in the US (000644): Daniel F. Soteres, Raffi Tachdjian, Maeve O'Connor, Chirag Maheshwari, Alice Wang, Paul K. Audhya, Timothy Craig. Results will be shared as a flash talk presentation from 9:21–9:28 am BST in the Dochart 1 room. Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks in Patients from Italy (D3.394): Mauro Cancian, Paola Triggianese, Pietro Accardo, Francesco Arcoleo, Donatella Bignardi, Caterina Colangelo, Francesco Giardino, Antonio Gidaro, Marica Giliberti, Maria Domenica Guarino, Paola Lucia Minciullo, Stefania Nicola, Francesca Perego, Riccardo Senter, Giuseppe Spadaro, Massimo Triggiani, Sherry Danese, Julie Ulloa, Vibha Desai, Paul Audhya, Andrea Zanichelli. Results will be shared as a poster presentation from 12:45–1:45 pm BST in the Poster Zone. Monday, June 16 Impact of Delayed Treatment of Hereditary Angioedema Attacks: Insights from Patient Surveys Across France, the United Kingdom, and the United States (000325): Alexis Bocquet, Paula J. Busse, Timothy Craig, Tariq El-Shanawany, Tomaz Garcez, Padmalal Gurugama, Rashmi Jain, Sorena Kiani-Alikhan, Maeve O'Connor, Cristine Radojicic, Sinisa Savic, H. James Wedner, Patrick Yong, Sherry Danese, Julie Ulloa, Vibha Desai, Paul K. Audhya, Sandra Christiansen. Results will be shared as a flash talk presentation from 11:34–11:41 am BST in the Dochart 2 room. KalVista is also sponsoring a symposium for healthcare professionals on Saturday, June 14, from 5:15–6:15 pm BST in the Alsh Ballroom, titled 'Closing Gaps in HAE Management: Understanding what control means for your HAE patients'. Chaired by Douglas Jones (USA), this panel discussion will feature presentations by Stephen Betschel (Canada), Thomas Buttgereit (Germany) and Sinisa Savić (UK). Links to all presentations can be found on the KalVista website under Publications. About Sebetralstat Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). We have filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older, with ongoing studies exploring its use in children aged 2 to 11. If approved, sebetralstat has the potential to become the foundational therapy for HAE management worldwide. About Hereditary Angioedema Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA, with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities. For more information about KalVista, please visit or follow us on social media at @KalVista and LinkedIn. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Business Wire
an hour ago
- Business Wire
Sonoma Biotherapeutics Announces Poster Presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)-- Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing a poster presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress, taking place in Barcelona on June 11-14, 2025. Details of the presentations are as follows: Poster Presentation Details: Title: 'REGULATE-RA: A Phase 1 Study of CAR-Treg Cells Targeting Citrullinated Proteins in Refractory Rheumatoid Arthritis: Interim Report of Patient Characteristics and Safety' Presenting Author: Sarah K. Baxter, MD, PhD Poster number: POS0034 Session: Clinical Poster Tours: Difficult to treat Rheumatoid Arthritis Date/ Time: Location: Poster Tour IV About Sonoma Biotherapeutics Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies. Sonoma Biotherapeutics is based in South San Francisco and Seattle. For more information, visit and follow on X, formerly Twitter, and LinkedIn.
